![Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials - The Lancet Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials - The Lancet](https://www.thelancet.com/cms/attachment/6a36b6d1-7069-4f30-aee2-808139178a60/gr2_lrg.jpg)
Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials - The Lancet
![Table 3 from The treatment of herpes simplex infections: an evidence-based review. | Semantic Scholar Table 3 from The treatment of herpes simplex infections: an evidence-based review. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/301f8b538b7a00695af50b7b9c0135497acddded/2-Table1-1.png)
Table 3 from The treatment of herpes simplex infections: an evidence-based review. | Semantic Scholar
![Table 2 from The treatment of herpes simplex infections: an evidence-based review. | Semantic Scholar Table 2 from The treatment of herpes simplex infections: an evidence-based review. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/301f8b538b7a00695af50b7b9c0135497acddded/3-Table2-1.png)
Table 2 from The treatment of herpes simplex infections: an evidence-based review. | Semantic Scholar
![Table 3 from The treatment of herpes simplex infections: an evidence-based review. | Semantic Scholar Table 3 from The treatment of herpes simplex infections: an evidence-based review. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/301f8b538b7a00695af50b7b9c0135497acddded/3-Table3-1.png)